Rapid detection of bladder cancer: A comparative study of point of care tests

Journal of Urology

Volumn 158, Issue 6, 1997, Pages 2098-2101

  Johnston, Brenda ^a   Morales, Alvaro ^a   Emerson, Laurel ^a   Lundie, Mark ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Bladder neoplasms; Cytology; Immunoassay; Markers; Tumor

Indexed keywords

FIBRINOGEN DEGRADATION PRODUCT; HEMOGLOBIN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; FEMALE; FIBRINOGEN METABOLISM; HEALTH ECONOMICS; HEMOGLOBIN DETERMINATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; URINE CYTOLOGY;

EID: 0030727827     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)68166-7     Document Type: Article

References (21)

1. Catalona, W. J.: Bladder cancer. In: Adult and Pediatric Urology, 2nd ed. Edited by J. Y. Gillenwater, J. T. Graychuck, S. S. Howards and J. W. Duckett. St. Louis: Mosby Year Book, vol. 1, chapt. 31, pp. 1135-1184, 1991.
2. Cordon-Cardo, C., Wartinger, D. D., Melamed, M. R., Fair, W. and Fradet, Y.: Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors. Amer. J. Path., 140: 375, 1992.
3. Soloway, M. S., Briggman, J. V., Carpinito, G. A., Chodak, G. W., Church, P. A., Lamm, D. L., Lang, P., Messing, E., Pasciak, R. M., Reservitz, G. B., Ruktsalis, D. B., Sarosdy, M. F., Stadler, W. M., Thiel, R. P. and Hayden, C. L.: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurrent transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol., 156: 363, 1966.
4. Briggman, J. V., Merrifield, S. A., Halvorsen, M. J. and Stolarek, S.: Measurement of a nuclear matrix protein in the urine of patients with bladder cancer. Proc. Ann. Meet. Amer. Assoc. Cancer Res., 35: A89, 1994.
5. Parry, W. L. and Hemstreet, G. P. III: Cancer detection by quantitative fluorescence image analysis. J. Urol., 139: 270, 1988.
6. Guirguis, R., Schiffmann, E., Liu, B., Birbeck, D., Engel, J. and Liotta, L.: Detection of autocrine motility factor in urine as a marker of bladder cancer. J. Natl. Cancer Inst., 80: 1203, 1988.
7. Müller, M., Heine, B., Heicappel, R., Hummel, M., Stein, H. and Miller, K.: Telomerase activity in bladder cancer, bladder washings and urine. J. Urol., part 2, 157: 337, abstract 187, 1997.
8. Wajsman, Z., Williams, P. D., Greco, J. and Murphy, G. P.: Further study of fibrinogen degradation products in bladder cancer detection. Urology, 12: 659, 1978.
9. Sarosdy, M. F., deVere White, R. W., Soloway, M. S., Sheinfield, J., Hudson, M. A., Schellhammer, P. F., Jarowenko, M. V., Adams, G. and Blumenstein, B. A.: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol., 154: 379, 1995.
10. Conn, I. G., Crocker, J., Wallace, D. M., Hughes, M. A. and Hilton, C. J.: Basement membranes in urothelial carcinoma. Brit. J. Urol., 60: 536, 1987.
11. Schmetter, B. S., Habicht, K. K., Lamm, D. L., Morales, A., Grossman, H. B., Bander, N., Hanna, M. G., Jr. and Butman, B. T.: A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J. Urol., 158: 801, 1997.
12. McCabe, R. P., Lamm, L. D., Haspel, M. V., Pomato, N., Smith, K. O., Thompson, E. and Hanna, M. G., Jr.: A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(ogen) degradation products. Cancer Res., 44: 5886, 1984.
13. Sofras, F., Nikolopoulou, R., Karagiannis, A. and Kostakopoulos, A.: Fibrin fibrinogen degradation products in bladder tumors. Eur. Urol., 18, suppl. 1: 31, 1990.
14. American Joint Committee on Cancer: Staging of cancer at genitourinary sites. In: Manual for Staging of Cancer, 3rd ed. Philadelphia: J. B. Lippincott Co., pp. 194-195, 1988.
15. Mostofi, F. K., Sobin, L. H. and Torloni, H.: Histological Typing of Urinary Bladder Tumours. Geneva: World Health Organization, 1973.
16. Mohr, D. N., Offord, K. P., Owen, R. A. and Melton, L. J. III: Asymptomatic microhematuria urological disease. A population base study. J.A.M.A., 256: 224, 1986.
17. D'Hallewin, M.-A. and Baert, L.: Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J. Urol., 155: 475, 1996.
18. Sarosdy, M. F., Hudson, M. A., Ellis, W. J., Soloway, M. S., deVere White, R. W., Sheinfield, J., Jarowenko, M. V., Schellhammer, P. F., Messing, E. M., Schervish, E. W., Patel, J. V., Chodak, G. W., Lamm, D. L., Johnson, R. D., Henderson, M., Adams, G., Blumenstein, B. A., Thoelke, K. R., Brunelle, S. L., Pfalzgraf, R. D. and Murchinson, H. A.: Detection of recurrent bladder cancer using a new one-step test for bladder tumor antigen. J. Urol., part 2, 157: 337, abstract 1318, 1997.
19. Ishak, L. M., Enfield, D. L., Redmond, W. A. and Sarodsky, M. F.: Detection of recurrent bladder cancer using a new quantitative assay for bladder tumor. J. Urol., part 2, 157: 337, abstract 1317, 1997.
20. Siemens, D. R., Johnston, B. L., Emerson, L. E. and Morales, A.: A comparative analysis of rapid urine testing for the diagnosis of transitional cell carcinoma (TCC) of the upper tracts. J. Urol., part 2, 157: 337, abstract 1275, 1997.
21. Badalament, R. A.: Editorial: More is simply more and not necessarily better. J. Urol., 156: 61, 1996.